On January 12, 2026, RIGL announced some preliminary Q4'25 financials, and some financial guidance for 2026. The first positive from that update is net product sales of ~$65.4M in Q4'25, aided by ...
6d
How The Narrative Around Rigel Pharmaceuticals (RIGL) Is Shifting With Raised Guidance And Cash Flow
Rigel Pharmaceuticals just saw its fair value estimate nudged from US$51.20 to US$51.60, a small move that still reflects some meaningful shifts in the story behind the stock. The model now blends ...
SOUTH SAN FRANCISCO, Calif., Aug. 5, 2025 /PRNewswire/ -- Rigel Pharmaceuticals (RIGL), Inc. , a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported ...
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is one of the Best Performing Affordable Stocks Under $40. On January 12, Rigel ...
Rigel Pharmaceuticals has seen its fair value estimate nudged up from US$49.60 to US$51.20, with only a small adjustment to the discount rate from 7.12% to 7.14% and revenue growth assumptions kept at ...
Rigel Pharmaceuticals (NASDAQ:RIGL) is gearing up to announce its quarterly earnings on Tuesday, 2025-11-04. Here's a quick overview of what investors should know before the release. Analysts are ...
SOUTH SAN FRANCISCO, Calif. and HOUSTON, Dec. 8, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and The University of Texas MD Anderson Cancer Center (MD Anderson) today announced a ...
SOUTH SAN FRANCISCO, Calif., June 25, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will effect a reverse stock split of its issued and outstanding shares of ...
Have you been paying attention to shares of Rigel Pharmaceuticals (RIGL)? Shares have been on the move with the stock up 73.3% over the past month. The stock hit a new 52-week high of $51.73 in the ...
Rigel Pharmaceuticals (RIGL) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...
For the second quarter ended June 30, 2025, total revenues were $101.7 million, consisting of $58.9 million in net product sales and $42.7 million in contract revenues from collaborations. Net product ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results